Question Bank › Selling into a customer's own emergency

Selling into a customer's own emergency

Calls Tested
496
Answered YES
12
Hit Rate
2.4%
rare by design

Palatin Technologies, Inc. (PTN) — this company's answers

NO on the Q4 2023 call 2023-09-29 D
The model's full reasoning — Q4 2023 call → NOThe question asks whether management describes the company's offering as relieving a pressing, costly problem the customer is already living with right now — an active pain, not a discretionary improvement. Looking at the transcript, the main products discussed are: 1. Vyleesi (for hypoactive sexual desire disorder in women) — commercial product 2. PL9643 (dry eye disease) — Phase III 3. PL8177 (ulcerative colitis) — Phase II 4. PL9588 (glaucoma) — preclinical 5. Erectile dysfunction combination (bremelanotide + PDE-5 inhibitor) The question is whether any of these are described as relieving an active, pressing problem customers are living with right now, with that dynamic already visible in the business. For Vyleesi: The company describes growth, refill rates, insurance reimbursement — but the description is about commercial metrics, not about the customer's active pain. HSDD is a chronic condition, but the call doesn't frame it as an emergency or pressing problem the customer is bleeding from. For dry eye disease: They describe the trial, efficacy, tolerability — but this is a clinical trial, not yet commercial. The urgency is about data readouts, not customer purchases. For erectile dysfunction: They mention 35% of men fail PDE-5 inhibitors and the only alternatives are invasive (penile injections or implants). This is interesting — it describes a patient population with an active problem (failed current therapy) and the alternatives are worse. But is this described as "already visible in the business now"? The program is being planned to initiate, not yet running. The description is about the market opportunity, not current orders or demand. For ulcerative colitis: Phase II trial, endpoints, enrollment — no customer pain described. The key test: Does management describe customers actively bleeding from a problem today, with that dynamic showing up in orders/urgency/behavior in the recent period? The ED program comes closest — patients who failed PDE-5 inhibitors have no good options, and the alternatives are invasive. But this is a planned program, not yet in the market. The urgency is anticipated, not current. Vyleesi is the only commercial product, and the call describes growth metrics but doesn't frame the customer's situation as a live emergency. HSDD is a quality-of-life condition, not described as a pressing, costly problem.

← Back to the full PTN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW — a shortage, failure, deadline, penalty, safety or compliance exposure, staffing gap, outage, backlog, spoilage, loss, or other pain the customer is actively bleeding from — such that the purchase functions as relief from an active problem rather than as an improvement, upgrade, or investment the customer could comfortably postpone? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation: the company's offering sits on the relief side of somebody else's live emergency, and buyers are acting accordingly today. Any genuine expression of this counts, and the form varies widely across industries. For example — management describing customers who cannot get something they need and are turning to this company to fill the gap; customers facing a deadline, mandate, court order, regulatory finding, audit, or contractual penalty that this company's product or service resolves; customers whose own operations are failing, breaking down, running short, running late, or losing money every day the problem persists, and who are buying to stop the loss; customers who cannot hire, cannot deliver, cannot produce, cannot comply, or cannot serve their own customers without what this company provides; buyers whose alternative to purchasing is an outcome plainly worse and more expensive than the price being charged; or management explaining that the spending decision is being made under duress rather than out of choice, and pointing to how that shows up in real orders, urgency, willingness to pay, or the kinds of conversations they are having now. Two things should come through in management's own voice. First, the customer's pain must be CONCRETE AND CURRENTLY ACTIVE — something the buyer is dealing with today, described specifically enough that one can see what goes wrong for the customer if nothing is bought — not a general claim that the product delivers value, saves money, or improves efficiency. Second, management must present this dynamic as ALREADY VISIBLE IN THE BUSINESS NOW — in orders, demand, urgency, pricing, or customer behavior in the recent period — rather than as a reason the market should eventually be large. Answer NO if the offering is described mainly in terms of benefits, savings, productivity, better performance, or attractive returns for the customer, however compelling — that is discretionary value, not relief from an active problem. NO if the pain described belongs to the company itself rather than to its customers. NO if the customer problem is generic or abstract ("customers face cost pressure," "the industry needs to modernize," "digital transformation is a priority"). NO if the urgency is only anticipated, forecast, or expected to emerge from some future rule, cycle, or condition not yet in force. NO if the buying pressure is attributed to a brief disruption management expects to pass and is not treating as characteristic of its market. NO if the only evidence is one isolated customer anecdote with no sense of a broader pattern. NO if management merely asserts that its product is essential, mission-critical, or non-discretionary without describing what the customer is actually up against. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
CEIX CONSOL Energy Inc. Q4 2022 2023-02-07 B
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
TENB Tenable Holdings, Inc. Q2 2021 2021-07-27 A
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
DHX DHI Group, Inc. Q2 2017 2017-07-28 D
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+

How the model reasoned

CEIX · Q4 2022 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES The transcript shows management describing customers buying coal to relieve an active shortage problem they are already facing. Key points include persistent coal supply shortages driving pricing, customers with low inventories (less than 20 days heading into winter), and spot needs in the back-half of the year. They also note Europe potentially relying on LNG after Russian gas depletes, and the supply of high-Btu coals still being constrained with demand remaining strong. This is presented as current market conditions visible in recent sales, pricing, and contracted volumes, not just a future improvement.
TENB · Q2 2021 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes customers facing active, ongoing cyber threats, ransomware attacks, high-profile breaches (e.g., Colonial Pipeline, Microsoft), and resulting business outages or disruptions that are driving immediate adoption of Tenable's solutions for continuous visibility, risk assessment, and prevention. This is framed as a current, pressing issue elevating discussions at the Board level and prompting purchases now, rather than future or optional improvements.
MITK · Q4 2017 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes the Equifax breach (earlier this year) as actively accelerating a "rapidly growing global problem" of verifying identity in a remote digital world, with enterprises turning to Mitek to "augment or replace traditional verification methods" because the Social Security number is "now widely breached" and "has run its race," making traditional methods "unsafe" and leading to fraud/identity theft.

More from the question bank

Analysts still asking about the old story whCenter of attention has moved to the newest Stale terms, scheduled resetLeaning into the stormManagement is playing referee between competTrajectory bent upward recently, and managemAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.